Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regeneron | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Regeneron

Global Eylea sales increased 13% to $1.7 billion in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron
2Q Revenues: $1.6 billion (+9%)
2Q Earnings: $551 million (+42%)
YTD Revenues: $3.1 billion (+12%)
YTD Earnings: $1.0 billion (+62%)
Comments: U.S. sales of EYLEA (aflibercept) Injection were up 8% to $992 million in the quarter and global sales increased 13% to $1.7 billion. The company recently submitted a supplemental Biologics License Application (sBLA) for EYLEA for the treatment of diabetic retinopathy and submitted an sBLA for EYLEA in a pre-filled syringe. Bayer records net product sales of EYLEA outside the U.S. and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters